氯维地平与尼卡地平在神经重症监护人群中急性降压的比较
本研究为回顾性研究,纳入2011年7月1日至2014年6月30日期间在本机构神经重症监护病房(NSICU)接受氯维地平或尼卡地平输注降压的患者,按降压指征和目标收缩压进行匹配。共纳入57例患者,氯维地平组达到目标收缩压的中位时间为30分钟,尼卡地平组为46分钟(p=0.13);目标血压范围内时间百分比分别为79%和78%(p=0.64)。氯维地平组每例患者给药体积显著少于尼卡地平组(530 mL vs 1254 mL,p=0.02)。结论认为两药在急性降压管理上无统计学显著差异,但氯维地平组有更短达标时间的趋势且给药体积显著更少,两种药物均可考虑作为NSICU人群的可行选择。
要点
- 在NSICU患者中,氯维地平组达到目标收缩压的中位时间为30分钟,尼卡地平组为46分钟,差异无统计学显著(p=0.13)。
- 目标血压范围内时间百分比氯维地平组为79%,尼卡地平组为78%,差异无统计学显著(p=0.64)。
- 氯维地平组每例患者给药体积为530 mL,显著少于尼卡地平组的1254 mL(p=0.02)。
- 作者认为两种药物均可考虑作为NSICU人群急性降压的可行选择。
适用人群与场景
- 2011年7月1日至2014年6月30日期间在本机构神经重症监护病房(NSICU)接受氯维地平或尼卡地平输注降压的患者,按降压指征和目标收缩压进行匹配。
研究设计与关键结果
- 研究为回顾性研究,共纳入57例患者,比较氯维地平与尼卡地平输注在NSICU患者中达到目标收缩压的时间及目标血压范围内时间百分比。
- 氯维地平组达到目标收缩压的中位时间为30分钟,尼卡地平组为46分钟(p=0.13)。
- 目标血压范围内时间百分比氯维地平组为79%,尼卡地平组为78%(p=0.64)。
- 氯维地平组每例患者给药体积为530 mL,尼卡地平组为1254 mL,氯维地平组显著少于尼卡地平组(p=0.02)。
证据类型、等级与局限
- 证据类型:回顾性研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在NSICU人群中,氯维地平和尼卡地平均可考虑作为急性降压的可行选择。
- 氯维地平组有更短达到目标收缩压时间的趋势,且给药体积显著更少。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Currently, a lack of published literature exists regarding the use of clevidipine in the neuroscience population. This agent may be preferred in some patients because of its short half-life, potentially leading to more narrow blood pressure (BP) control in comparison with other agents. The purpose of this study was to compare the difference in time to achieve target systolic blood pressure (SBP) goals with clevidipine versus nicardipine infusions in patients admitted to the neuroscience intensive care unit (NSICU) at our institution.
METHODS: A retrospective review was performed on patients receiving clevidipine or nicardipine infusions while in the NSICU between July 1, 2011 and June 30, 2014. Patients were matched based on indication for BP lowering and target SBP. Primary endpoints included time to target SBP and percentage of time within target BP range.
RESULTS: Of the 57 patients included in the study, the median time to target SBP was 30 min in the clevidipine group and 46 min in the nicardipine group (p = 0.13). The percentage of time spent within target BP range was 79 versus 78% (p = 0.64). Clevidipine administration resulted in significantly less volume administered per patient versus nicardipine (530 vs. 1254 mL, p = 0.02).
CONCLUSIONS: There were no statistically significant differences in acute BP management between the two agents; however, there was a trend toward shorter time to target and significantly less volume administered in the clevidipine group. Either agent should be considered a viable option in a NSICU population.
参考来源
- Finger JR, Kurczewski LM, Brophy GM, et al. Clevidipine Versus Nicardipine for Acute Blood Pressure Reduction in a Neuroscience Intensive Care Population. Neurocrit Care. 2017. PMID: 27995512. doi:10.1007/s12028-016-0349-4
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。